Advances in uro-oncology «oncoforum»: The best of 2011;Avances en uro-oncología «oncoforum»: lo mejor de 2011

Actas Urologicas Espanolas

Volumn 36, Issue 9, 2012, Pages 507-514

  Gomez Veiga F ^a   Alcaraz Asensio, A ^b   Burgos Revilla, J ^c   Cozar Olmo J ^d  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Kidney cancer; Penile cancer; Prostate cancer; Testicular cancer; Urinary bladder cancer; Urology

Indexed keywords

ARTICLE; BLADDER TUMOR; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; EUROPE; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MALE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); ONCOLOGY; ORGANIZATION; PENIS TUMOR; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TESTIS TUMOR; TREATMENT OUTCOME; UNITED STATES; UROLOGY;

CONGRESSES AS TOPIC; CONTROLLED CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; EUROPE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; PENILE NEOPLASMS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER NEOPLASMS; UROLOGY;

EID: 84865861627     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2012.02.001     Document Type: Article

References (38)

1. F. Gómez-Veiga, A. Alcaraz-Asensio, J. Burgos-Revilla, and J.M Cózar-Olmo [Advances in uro-oncology OncoForum: the best of 2010] Actas Urol Esp 35 2011 315 324
2. P.J. Van Leeuwen, M.J. Roobol, M. Bul, X. Zhu, and F.H. Schröder The positive effect of prostate cancer screening on metastatic disease is increasing Eur Urol Suppl 10 2011 33 (abs.15)
3. http://webcasts.prous.com/AUA2011/html/1-en/template.aspx?section= 7&p=7,18082
4. P. Sooriakumaran, M. John, R. Leung, D. Peters, D. Lee, and P. Wiklund A multi-institutional study of 3,794 patients undergoing robotic-assisted laparoscopic radical prostatectomy shows the learning curve is not as short as previously thought Eur Urol Suppl 10 2011 127 (abs.349)
5. P. Sooriakumaran, M. John, P. Wiklund, D. Lee, A. Nilsson, and A.K. Tewari Learning curve for robotic assisted laparoscopic prostatectomy: a multi-institutional study of 3,794 patients Minerva Urol Nefrol 63 2011 191 198
6. S. Joniau, P. Gontero, A. Briganti, G. Marchioro, U. Capitanio, and P. Bader The number of positive section margins in high-risk prostate cancer is a powerful and independent predictor of cancer-specific and overall survival in high-risk localized prostate cancer J Urol 185 4 Suppl 2011 e191 (abs.471)
7. C. Mazzola, Y. Ahallal, T. Ghoneim, D. Sjoberg, B. Guillonneau, and J. Eastham Long-term outcomes for prostate cancer patients with lymph node metastasis after radical prostatectomy J Urol 185 4 Suppl 2011 e121 (abs.298)
8. L. Colette, M. Bolla, and H. Van Poppel Adjuvant radiation for pathologically advanced prostate cancer: a head to head comparison of SWOG and EORTC trials Eur Urol Suppl 10 2011 90 91 (abs.218)
9. C.R. King The optimal timing of salvage radiotherpy following radical prostatectomy: a meta-analysis Int J Radiat Oncol Biol Phys 81 2 Suppl 2011 S73 S74 (abs.144)
10. P.L. Nguyen, Y. Je, F.A.B. Schutz, K.E. Hoffman, J.C. Hu, and J.A. Beckman Meta-analysis of the impact of androgen deprivation therapy on cardiovascular death in patients with prostate cancer Int J Radiat Oncol Biol Phys 81 2 Suppl 2011 S6 (abs.10)
11. P.L. Nguyen, Y. Je, F.A.B. Schutz, K.E. Hoffman, J.C. Hu, and A. Parekh Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer. A meta-analysis of randomized trials JAMA 306 2011 2359 2366
12. J.M. Crook, C.J. O'Callagham, K. Ding, G. Duncan, D.P. Dearnaley, and C.S. Higano A phase iii randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013) J Clin Oncol 29 15S 2011 292s (abs.4514)
13. G.G. Duncan, C. O'Callaghan, K. Ding, D.P. Dearnaley, C. Higano, and E. Horwitz QoL/outcomes of an international phase 3 trial of intermittent v continuous hormone therapy for relapsed prostate Ca Radiother Oncol 99 Suppl 1 2011 S210 (abs.517)
14. U.E. Studer, P. Whelan, W. Albrecht, F. Wimpissinger, J. Casselman, and T.M. De Reijke Immediate or deferred androgen deprivation for patients with prostate cancer and no local treatment of the prostate Long term results of EORTC 30891 Eur Urol Suppl 10 2011 254 (abs.804)
15. K. Fizazi, J. De Bono, C. Haqq, C.C. Logothetis, R.J. Jones, and K. Chi Abiraterone acetate plus low-dose prednisone has a favorable safety profile in metastatic castration-resistant prostate cancer progressing after docetaxel-based chemotherapy: results from COU-AA-301, a randomised, double-blind, placebo-controlled, phase iii study Eur Urol Suppl 10 2011 338 (abs.1098)
16. J.S. De Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, and L. Chu Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
17. C. Higano, T. Beer, E. Yu, M.E. Taplin, E. Efstathiou, and A. Anand Long-term efficacy results from the phase 1-2 study on MDV3100 in pre- and post-docetaxel advanced prostate cancer Eur Urol Suppl 10 2011 338 (abs.1099)
18. M. Hussain, M.R. Smith, C. Sweeney, P.G. Corn, A. Elfiky, and M.S. Gordon Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase ii randomized discontinuation trial J Clin Oncol 29 15S 2011 293s (abs.4516)
19. M.R. Smith, F. Saad, R. Coleman, N. Shore, K. Fizazi, and B. Tombal Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial Lancet 379 2012 39 46
20. N. Mottet, J. Bellmunt, M. Bolla, S. Joniau, M. Mason, and V. Matveev [EAU guidelines on prostate cancer Part ii: treatment of advanced, relapsing, and castration-resistant prostate cancer] Actas Urol Esp 35 2011 565 579
21. T. O'Brien, K. Chatterton, E. Ray, A. Chandra, S. Khan, and K. Thomas A prospective trial of hexylaminolevulinate (HAL) assisted transurethral resection (TURBT) plus single shot intravesical mitomycinC (MMC) versus white light TURBT plus single shot MMC in newly presenting bladder cancer J Urol 185 4 Suppl 2011 e661 (abs.1647)
22. A. Orsola, C. Raventós, M. Allué, F. Lozano, G. Delgado, and J.M. Bastarós Optimizing therapeutic strategies in initial high grade T1 bladder cancer: post-BCG second TUR according to lamina propria invasion microstaging (T1a/b) J Urol 185 4 Suppl 2011 e703 (abs.1752)
23. A. Morales, H. Herr, A. Kamat, G. Steinberg, R. Given, and C. Lihou Phase 3 study to evaluate the efficacy and safety of mycobacterial cell wall-DNA complex in the treatment of patients with non-muscle invasive bladder cancer at high risk of progression and who are refractory to BCG J Urol 185 4 Suppl 2011 e662 e663 (abs.1650)
24. B.W.G. Van Rhijn, P.J. Bostrom, S.F. Shariat, A. Finelli, A.I. Sagalowsky, and N.E. Fleshner The FGFR 3 mutation identifies patients with favorable disease at radical cystectomy for bladder cancer Eur Urol Suppl 10 2011 243 (abs.765)
25. F. Abdollah, J. Schmitges, M. Sun, C. Jeldres, D. Liberman, and Z. Tian Stage-specific impact of pelvic lymph node dissection (PLND) on survival in patients with non-metastatic bladder cancer treated with radical cystectomy (RC) Eur Urol Suppl 10 2011 272 273 (abs.865)
26. F. Abdollah, M. Sun, J. Schmitges, O. Djahangirian, Z. Tian, and C. Jeldres Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy BJU Int 2011 epub. doi:10.1111/j.1464-410X.2011.10482.x.
27. D. Londono, M. Wuerstle, T. Danial, and G. Chien Accuracy and implication of percutaneous renal biopsy in the management of renal masses J Urol 185 4 Suppl 2011 e279 e280 (abs.695)
28. S.M. Desmukh, L. Sequeira, F. McGovern, D. Dahl, A. Olumi, and B. Eisner Percutaneous biopsy of suspicious cystic renal masses: what is the diagnostic yield? J Urol 185 4 Suppl 2011 e282 (abs.701).
29. S.M. Desmukh, L. Sequeira, F. McGovern, D. Dahl, A. Olumi, and B. Eisner Percutaneous renal mass biopsy: If they're positive, they're positive, but if they're negative, be careful! A correlation between renal biopsy and surgical pathology J Urol 185 4 Suppl 2011 e283 (abs.704)
30. M. Kates, G.M. Badalato, N. Sadeghi, M.S. Pitman, and J.M. McKiernan Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma less than or equal to 2 cm J Clin Oncol 29 15S 2011 310s (abs.4589)
31. M. Kates, G.M. Badalato, M. Pitman, and J.M. McKiernan Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma 2 cm or less J Urol 186 2011 1247 1253
32. R. Abousassaly, S.M.H. Alibhai, G.A. Tomlinson, D.R. Urbach, and A. Finelli The effect of age on the morbidity of kidney surgery in general clinical practice J Urol 185 4 Suppl 2011 e669 (abs.1665)
33. R. Abousassaly, S.M.H. Alibhai, G.A. Tomlinson, D.R. Urbach, and A. Finelli The effect of age on the morbidity of kidney surgery J Urol 186 2011 811 816
34. R.A. Fisher, A. Pender, K. Thillai, S. Chowdhury, L.M. Pickering, and S.S. Rose Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era J Clin Oncol 29 15S 2011 321s (abs.4630)
35. B.I. Rini, D. Escudier, P. Tomczak, A. Kaprin, T.E. Hutson, and C. Szczylik Axitinib versus sorafenib as second-line therapy for metastaic renal cell carcinoma (mRCC): Results of phase iii AXIS trial J Clin Oncol 29 15S 2011 289s (abs.4503)
36. B.I. Rini, D. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, and T.E. Hutson Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase iii trial Lancet 2011 epub. doi:10.1016/S0140-6736(11)61613-9
37. D. Pfister, J. Bush, M. Schrader, C. Winter, P. Albers, and K.P. Dieckmann Pathohistological findings in patients with nonseminomatous germ cell tumours (NSGCT) who undergo post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for small tumours Eur Urol Suppl 10 2011 319 (abs.1031).
38. S. Radhakrishnan, S. Hughes, and P. Bose Active surveillance of inguinal lymph nodes after treatment of primary penile cancer-a prospective study Eur Urol Suppl 10 2011 341 (abs.1110)